[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100356800":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":42,"centralContacts":56,"locations":63,"responsibleParty":81,"collaborators":61,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":61,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":61,"enrollmentInfo":93,"targetDuration":61,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":61,"overallStatus":66,"whyStopped":61,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Tanta University","OTHER",[8,13,19],{"label":9,"type":6,"description":10,"interventionNames":11},"life style","life style control only",[12],"Other: life style",{"label":14,"type":15,"description":16,"interventionNames":17},"Metformin","ACTIVE_COMPARATOR","Metformin 500 mg twice daily",[18],"Drug: Metformin",{"label":20,"type":21,"description":22,"interventionNames":23},"Nigetella salivata","EXPERIMENTAL","NS 450 mg twice daily",[24],"Drug: Nigetella salivata",[26,31,37],{"type":6,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"life sryle control only",[9],[30],"life style management",{"type":32,"name":14,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","metformin twice daily",[14],[36],"cidophage",{"type":32,"name":20,"description":38,"armGroupLabels":39,"otherNames":40},"NS twice daily",[20],[41],"NS",[43,47,49,52],{"name":44,"affiliation":45,"role":46},"Eman SA Sawan, Msc","Tanta University - Faculty of Pharmacy","PRINCIPAL_INVESTIGATOR",{"name":48,"affiliation":45,"role":46},"Sahar Hegazy, Prof",{"name":50,"affiliation":45,"role":51},"Tarek Mostafa, ass. Prof.","STUDY_DIRECTOR",{"name":53,"affiliation":54,"role":55},"Sherin El-Nidany, MD","Tanta University-Faculty of pharmacy","STUDY_CHAIR",[57],{"name":58,"role":59,"phone":60,"phoneExt":61,"email":62},"Sherief Abd-Elsalam, ass. prof.","CONTACT","00201147773440",null,"sheriefabdelsalam@yahoo.com",[64],{"facility":65,"status":66,"city":67,"state":61,"zip":61,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Sherief Abd-Elsalam","RECRUITING","Cairo","Egypt","EG",{"type":71,"coordinates":72},"Point",[73,74],31.24967,30.06263,{"lat":74,"lon":73},[77],{"name":78,"role":59,"phone":79,"phoneExt":61,"email":80},"Sherief Abd-elsalam, lecturer","00201000040794","Sherif_tropical@yahoo.com",{"type":82,"investigatorFullName":65,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":61,"oldOrganization":61},"SPONSOR_INVESTIGATOR","Ass. Prof. Tropical Medicine","100356800","phase-3-impact-of-p53-and-sirt1-in-type-2-diabetes-100356800",false,"NCT03925714","Impact of P53 and SIRT1 in Type 2 Diabetes","Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin","Inclusion Criteria:\n\n* Prediabetic subjects.\n\nExclusion Criteria:\n\n* Confirmed diabetes.\n* Hepatic or renal impairment.","ALL","18 Years",{"count":94,"type":95},90,"ESTIMATED","INTERVENTIONAL",[98],"PHASE3","Investigating the impact of p53 and SIRT1 in the development of type 2 DM",[101],"DM","2019-04-22",{"date":104,"type":105},"2019-04-24","ACTUAL",{"date":107,"type":105},"2019-04-01",{"date":109,"type":95},"2028-12",{"name":65,"class":6},1]